1Gregoratos G, Abrams J, Epstein AE,et al. ACC/ AHA/ NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices (ACC/ AHA/ NASPE Committee to Update the 1998 Pacemaker Guidelines) .Circulation, 2002, 106: 2145-2161.
2Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med, 2002, 346:877-883.
4Buxton AE. The clinical use of implantable cardioverter defibrillators: where are we now? where should we go? Ann Intern Med, 2003, 138: 512-514.
5Reynolds MR, Josephson ME. MADIT Ⅱ(Second Multicenter Automated Defibrillator Implantation Trial) debate: risk stratification, costs, and public policy. Circulation,2003, 108:1779-1783.
6Zheng ZJ, Croft JB, Giles WH, et al. Sudden cardiac death in the United States 1989 to 1998. Circulation, 2001, 104:2155-2163.
7Seidl K, Sengs J. Worldwide utilization of implantable cardioverter/ defibrillators: now and in the future. Cardiac Electrophysiol Review, 2003, 7:5-13.
8Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo, the Cardiac Arrhythmia Suppression Trial. N Engl J Med,1991, 324:781-788.
9Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med, 1996, 335:1933-1940.
10Ezekowitz JA, Armstrong PW, Mc Alister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med ,2003, 138:445-452.
8Furburg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction [ J ]. Am J Cardiol, 1983,52:32c-36c.
9Gittlib SH, Achuff SC, Mellits ED, et al. Prophylactic antiarrhythmic therapy of high-risk survivors of myocardial infarction:lower mortality at 1 month but not at 1 year[ J ]. Circulation, 1987,75:792-799.
10Echt DS,Liebson PR,Mitchell LB.et al. Morbidity and morbidity in patients receiving flecainide or placebo. The Cardiac Arrhythmia Suppression Trial [ J ]. N Engl J Med, 1991,324:781-788.
